GALT Galectin Therapeutics Inc.

2.8
-0.04  -1%
Previous Close 2.84
Open 2.81
Price To Book 3.37
Market Cap 159,218,391
Shares 56,886,059
Volume 79,417
Short Ratio
Av. Daily Volume 298,151
Stock charts supplied by TradingView

NewsSee all news

  1. Galectin Therapeutics' Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology

    NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of

  2. Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis

    Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin, CEO, Discusses Plan at Annual

  3. Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders

    NORCROSS, Ga., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H. Shlevin, Ph.D., president

  4. Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit

    NORCROSS, Ga., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer, Ph.D., Vice President,

  5. Galectin Therapeutics Reports Q3 2019 Financial Results

    NORCROSS, Ga., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 1Q 2020 with top-line data due 4Q 2022.
GR-MD-02
Non-alcoholic steatohepatitis (NASH) with cirrhosis
Phase 1b data released September 20, 2018. ORR 50%.
GR-MD-02 and pembrolizumab (KEYTRUDA)
Melanoma
Phase 2a interim data released May 2016
GR-MD-02
moderate-to-severe plaque psoriasis.

Latest News

  1. Galectin Therapeutics' Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology

    NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of

  2. Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis

    Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin, CEO, Discusses Plan at Annual

  3. Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders

    NORCROSS, Ga., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H. Shlevin, Ph.D., president

  4. Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit

    NORCROSS, Ga., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer, Ph.D., Vice President,

  5. Galectin Therapeutics Reports Q3 2019 Financial Results

    NORCROSS, Ga., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business

  6. Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

    NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens

  7. Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting

    NORCROSS, Ga., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained

  8. Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy

    NORCROSS, Ga., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have